Scoop: After failing to secure more funds, a private gene therapy developer lays off staff

Kyle LaHucik

Senior Reporter

Last Friday, SwanBio Therapeutics laid off about one-quarter of its 60-person workforce, a person with knowledge of the matter told Endpoints News.

The gene therapy …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Scoop: After failing to secure more funds, a private gene therapy developer lays off staff

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Scoop: Af­ter fail­ing to se­cure more funds, a pri­vate gene ther­a­py de­vel­op­er lays off staff

Senior Reporter

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Scoop: After failing to secure more funds, a private gene therapy developer lays off staff